HIPEC in ovarian cancer: What should we expect?

被引：1
|
作者：
Picard, Leonie [1 ]
Bourgin, Charlotte [2 ]
Penault-Llorca, Frederique [1 ]
Beguinot, Marie [1 ]
Cornou, Caroline [1 ]
Le Bouedec, Guillaume [1 ]
Mouret-Reynier, Marie-Ange [1 ]
Selle, Frederic [3 ]
Pomel, Christophe [1 ]
机构：
[1] Ctr Jean Perrin, 58 Rue Montalembert, F-63011 Clermont Ferrand, France
[2] Inst Cancerol Ouest, 15 Rue Andre Boguel, F-49055 Angers, France
[3] Hop Diaconesses, 12-18 Rue Sergent Bauchat, F-75012 Paris, France
来源：
BULLETIN DU CANCER | 2019年 / 106卷 / 11期
关键词：
HIPEC; Ovarian; Carcinomatosis; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; INTERVAL DEBULKING SURGERY; CYTOREDUCTIVE SURGERY; ONCOLOGY-GROUP; STAGE-III; DOUBLE-BLIND; CISPLATIN; BEVACIZUMAB; PACLITAXEL; MULTICENTER;
D O I：
10.1016/j.bulcan.2019.04.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The results of PRODIGE 7 study demonstrate that the use of HIPEC is not beneficial for patients in the treatment of colorectal carcinomatosis. Nevertheless, a recent study published in New England Journal of Medicine showed that hyperthermic intraperitoneal chemotherapy (HIPEC) increased overall survival for patients with ovarian peritoneal carcinomatosis. Although, the emergence of targeted therapies (anti-angiogenic agents, PARP-inhibitors, anti-PDL1) results in new standards of treatment in first line or recurrence disease. In this general context, what is the potential interest of HIPEC for the treatment of ovarian carcinoma?
引用
收藏
页码：1023 / 1028
页数：6
相关论文
共 50 条
  • [41] What Should We Expect from the Next Guidelines on Hypertension?
    Massimo Volpe
    High Blood Pressure & Cardiovascular Prevention, 2005, 12 (4) : 199 - 202
  • [42] What should we expect from a modern urethral lubricant?
    Sperling, H.
    Ruebben, H.
    Luemmen, G.
    BJU INTERNATIONAL, 2011, 107 : 23 - 23
  • [43] RESEARCH AND ECONOMIC-GROWTH - WHAT SHOULD WE EXPECT
    WILLIAMS, BR
    MINERVA, 1964, 3 (01) : 57 - 71
  • [44] COVID-19 and Diabetes: What Should We Expect?
    Pedrosa, Marlus da Silva
    Neves Nogueira, Fernando
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2020, 14 (06): : 1133 - 1134
  • [45] Dupilumab and COVID-19: What should we expect?
    Patruno, Cataldo
    Stingeni, Luca
    Fabbrocini, Gabriella
    Hansel, Katharina
    Napolitano, Maddalena
    DERMATOLOGIC THERAPY, 2020, 33 (04)
  • [46] WHAT SHOULD WE EXPECT FROM PARALLEL LANGUAGE STANDARDS
    PANCAKE, CM
    BAILEY, R
    BARKAI, D
    SMITH, B
    BRANDENBURG, J
    DONGARRA, J
    KALOS, M
    SNIR, M
    GELERNTER, D
    INTERNATIONAL JOURNAL OF SUPERCOMPUTER APPLICATIONS AND HIGH PERFORMANCE COMPUTING, 1992, 6 (01): : 112 - 117
  • [47] Extracellular matrix of senescent cells: What should we expect?
    Sa Ferreira, R.
    Pitrez, P.
    Quaas, M.
    Pompe, T.
    Ori, A.
    Passos, J.
    Ferreira, L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 : 119 - 119
  • [48] Combination antifungal therapy: what can and should we expect?
    Johnson, M. D.
    Perfect, J. R.
    BONE MARROW TRANSPLANTATION, 2007, 40 (04) : 297 - 306
  • [49] Combination antifungal therapy: what can and should we expect?
    M D Johnson
    J R Perfect
    Bone Marrow Transplantation, 2007, 40 : 297 - 306
  • [50] New Ag Guide-What should we expect?
    Webster, A. B.
    JOURNAL OF ANIMAL SCIENCE, 2016, 94 : 14 - 14
12345